Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

COBIK

Ownership
Private
Employees
~28
Therapeutic Areas
Rare DiseasesInfectious Diseases
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Nucleic acid therapyViral vector therapyProtein nanoparticle therapyVirus-like particle therapySmall molecule

COBIK General Information

COBIK develops vaccines, gene therapies, and antibacterial products using advanced modalities such as nucleic acids, viral vectors, protein nanoparticles, and virus-like particles. The company has founded several spinouts to advance programs into pre-clinical and clinical trials. It is recognized for its innovation in bioprocessing workflows and collaborative projects with academic and industry partners. Specific clinical results are not publicly detailed but the company is active in proof-of-concept through early clinical stages.

Contact Information

Website
https://www.cobik.si/
Primary Industry
Biotech
Corporate Office
Ajdovščina,
Slovenia

Drug Pipeline

No pipeline data available

For full access to COBIK's pipeline data

Book a demo

Key Partnerships

Academic institutions via Biopharm.si & Smartgene.si projects

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

COBIK Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view COBIK's complete valuation and funding history, request access »

COBIK Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals